Hot Stock
Diese Aktie steigt um 225%! Ist ein Kupfer-Engpass im Gange?!
Anzeige
Austausch für VIDAC WKN: A3DTUQ ISIN: GB00BM9XQ619 Kürzel: T9G Forum: Aktien User: speculator
0,78 EUR
-1,89 %-0,02
18. Oct, 20:54:06 Uhr,
Stuttgart
Kommentare 1.976
Consti22,
12.06.2024 20:52 Uhr
0
Jetzt haben wir schon mal ne gute Analysteneinschätzung und was macht der Kurs? 🤦♂️ Die Aktie macht mich fertig. 🙄🤣🤣🤣
Transalp,
12.06.2024 19:52 Uhr
1
Wow das sind mal Aussichten.
Da halte ich doch mal glatt bis 4,90€ 🥳🥳🥳
J
Jan19881988,
12.06.2024 19:14 Uhr
0
Kommt rein !!
V
Venturi,
12.06.2024 19:11 Uhr
1
Kursziel 4,90!!!
Orestis73,
12.06.2024 17:38 Uhr
0
um 14:36:30 Uhr
Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
^
Original-Research: Vidac Pharma Holding Plc - from Sphene Capital GmbH
Classification of Sphene Capital GmbH to Vidac Pharma Holding Plc
Company Name: Vidac Pharma Holding Plc
ISIN: GB00BM9XQ619
Reason for the research: Initiation of Coverage
Recommendation: Buy
from: 12.06.2024
Target price: EUR 4.90
Target price on sight of: 36 months
Last rating change: -
Analyst: Peter Thilo Hasler
Reversal of the abnormal metabolism of cancer cells
We initiate research coverage of the shares of Vidac Pharma Holding plc
with a Buy rating and a price target of EUR 4.90 (base case scenario). Our
price target is based on the assumption that Vidac Pharma will get approval
for its current core product VDA-1102-AK. We derive our price target from a
three-stage discounted cash flow entity model (primary valuation method).
In a Monte Carlo analysis, we have used alternative sales, earnings and
other KPI scenarios and calculate equity values in a range between EUR 4.04
and EUR 5.40 per share. Based on our capital and earnings estimates for
2028e-33e, an economic profit model-which we used as a secondary valuation
method-results in equity values of up to EUR 6.50 per share (discounted
with the cost of equity), with a clear upward trend over time, illustrating
the logic of a long-term investment in Vidac Pharma shares, in our view.
Established in 2012 by Dr Max Herzberg, one of the founding fathers of the
Israeli life sciences industry, Vidac Pharma is a clinical-stage
biopharmaceutical company specialising in oncology and oncodermatology
therapies. The therapies developed by Vidac Pharma aim to fight cancer by
reversing the abnormal metabolism of cancer cells. Clinical tests have
shown that the overexpression of hexokinase 2 (HK2) and its binding to
VDAC1 on the outer mitochondrial membrane of cancer cells is the key to
their metabolic reprogramming to anaerobic glycolysis, which enables tumour
cells to proliferate so drastically in the first place. An allosteric small
molecule that modifies HK2 so that it cannot bind to mitochondria can
therefore reduce glycolysis and induce apoptosis in cancer cells without
affecting HK1-expressing normal cells.
Currently, Vidac Pharma has two drugs in the development pipeline:
VDA-1102, an ointment for the topical, i.e. dermal treatment of patients
with actinic keratosis (AK)-a potentially premalignant disease of the skin
and main risk factor for the development of cutaneous squamous cell
carcinoma (currently in Phase 2b)-as well as for the treatment of cutaneous
T-cell lymphoma (currently in Phase 2a), and the active ingredient
VDA-1275, which is being developed for the systemic treatment of solid
tumours (currently in a preclinical Phase).
You can download the research here:
http://www.more-ir.de/d/30019.pdf
Contact for questions
Peter Thilo Hasler, CEFA
+49 (152) 31764553
-------------------transmitted by EQS Group AG.-------------------
The issuer is solely responsible for the content of this research.
The result of this research does not constitute investment advice
or an invitation to conclude certain stock exchange transactions.
°
Consti22,
12.06.2024 15:08 Uhr
1
Oh, es tut sich was. Das ist die allererste Analystenbewertung. Und Kaufempfehlung. 💪😊
Consti22,
12.06.2024 15:07 Uhr
1
https://de.marketscreener.com/kurs/aktie/VIDAC-PHARMA-HOLDING-PLC-153144154/news/Vidac-Pharma-Holding-Plc-von-Sphene-Capital-GmbH-Buy-46957837/
LupoM,
11.06.2024 21:03 Uhr
1
Vielleicht haben die 100 000 Stück wissen wir es. Bei wenig Volumen kann viel sein.
Es müssen Ergebnise her. Es muss was großes sein , sonst merkt es keiner das es die Aktie gibt und steigen kann
A
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Lilium Aktie | ±0,00 % | |
2 | BTC/USD Hauptdiskussion | -0,19 % | |
3 | MicroStrategy | +0,11 % | |
4 | EcoGraf Hauptdiskussion | ±0,00 % | |
5 | CARNAVALE RESOURCES Hauptdiskussion | ±0,00 % | |
6 | BRITISH AMERICAN TOBACCO Hauptdiskussion | ±0,00 % | |
7 | Samsung SDI eine der innovativsten Globalplayer in Sachen in Sachen Energiespeicher. | ±0,00 % | |
8 | VOESTALPINE Hauptdiskussion | ±0,00 % | |
9 | NVIDIA Hauptdiskussion | -0,16 % | |
10 | fox e-mobility Hauptdiskussion | ±0,00 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | Lilium Aktie | ±0,00 % | |
2 | MicroStrategy | +0,11 % | |
3 | EcoGraf Hauptdiskussion | ±0,00 % | |
4 | CARNAVALE RESOURCES Hauptdiskussion | ±0,00 % | |
5 | BRITISH AMERICAN TOBACCO Hauptdiskussion | ±0,00 % | |
6 | VOESTALPINE Hauptdiskussion | ±0,00 % | |
7 | NVIDIA Hauptdiskussion | -0,16 % | |
8 | fox e-mobility Hauptdiskussion | ±0,00 % | |
9 | Samsung SDI eine der innovativsten Globalplayer in Sachen in Sachen Energiespeicher. | ±0,00 % | |
10 | AMERICAN LITHIUM Hauptdiskussion | ±0,00 % | Alle Diskussionen |